NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference

NeuroPace, Inc. (Nasdaq: NPCE), a pioneering medical device company dedicated to improving the lives of individuals with epilepsy, has announced that its management team will present at the upcoming 44th Annual J.P. Morgan Healthcare Conference. Scheduled for January 14, 2026, at 3:00 PM PT in San Francisco, this presentation is an important opportunity for the company to showcase its advancements and engage with investors. Attendees will also have the chance to participate in investor meetings during the conference.

NeuroPace’s impressive RNS System stands out as a groundbreaking technology in the epilepsy treatment landscape. This platform, which is the first of its kind, offers a brain-responsive treatment option that delivers personalized and real-time interventions directly at the seizure source. It aims to significantly reduce or even eliminate the occurrence of seizures, particularly for patients suffering from drug-resistant epilepsy. The RNS System is poised to enhance the standard of care for this population and holds promise for addressing a wider array of brain disorders through personalized medical approaches.

The presentation at the J.P. Morgan Healthcare Conference will be available via live webcast, allowing stakeholders who cannot attend in person to stay informed. A replay of the webcast will also be made available for 30 days following the event on NeuroPace’s Investor website, ensuring continued access to this vital information.

NeuroPace, headquartered in Mountain View, California, remains committed to leveraging innovative technology to transform epilepsy treatment and improve patient outcomes. For further inquiries, investors can contact Scott Schaper, the Head of Investor Relations at NeuroPace.

As NeuroPace, Inc. (Nasdaq: NPCE) prepares to present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, it’s an opportune moment for investors to analyze the company's strategic positioning and market potential. With its innovative RNS System, which has been a game-changer for patients with drug-resistant epilepsy, NeuroPace not only addresses a significant unmet medical need but also demonstrates a commitment to personalized medicine.

Investors should pay close attention to the details shared during the conference as the management team outlines growth strategies, clinical data, and market expansion plans. Key topics to anticipate include updates on ongoing clinical trials, partnerships, and regulatory developments that could further enhance NeuroPace’s competitive edge. The presentation also serves as an opportunity for management to discuss initiatives aimed at improving marketing and education around the RNS System, critical for adoption in more challenging markets.

With the global epilepsy treatment market projected to grow significantly, NeuroPace stands to benefit from rising awareness and recognition of its technology, which has the potential to revolutionize care for not just epilepsy but other brain disorders as well. Investors should also consider the potential risks, including competition from emerging treatments and devices, along with reimbursement challenges.

In conclusion, as NeuroPace presents at this prestigious conference, informed investors should evaluate both the potential for growth and the competitive landscape. The webcast replay and follow-up investor meetings provide an avenue for deeper engagement, enabling stakeholders to refine their investment strategies around this promising player in the medical device sector.